Edition:
United States

Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Orexigen Therapeutics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

23 Sep 2016 Reuters Investment Profile 12 $20.00

Orexigen Therapeutics

24 Sep 2016 S&P Capital IQ Quantitative Report 10 $115.00

OREX: Updated Model: Forensic Earnings and Valuation

Reports provide superior value and incorporate critical data from the Financial Footnotes and MD&A that other firms miss. The...

23 Sep 2016 New Constructs, LLC 10 $25.00

Value Graph: OREXIGEN THERAPE -- OREX

23 Sep 2016 Ford Investor Services, Inc. 1 $12.00

Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of OREXIGEN THERAPEUTICS INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.

23 Sep 2016 Jefferson Research 11 $20.00

Orexigen Therapeutics, Inc. (OREX) - Financial and Strategic SWOT Analysis Review

Orexigen Therapeutics, Inc. (OREX) - Financial and Strategic SWOT Analysis Review Summary Orexigen Therapeutics, Inc. (Orexig...

19 Sep 2016 GlobalData 59 $300.00

ValuEngine Rating and Forecast Report for OREX

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and...

18 Sep 2016 ValuEngine, Inc. 11 $25.00

OREXIGEN THERAPEUTICS INC (OREX=US) - SHORT AND LONG TERM FORECASTS FOR ACTIVE TRADERS

"www.pechala.com, the world's largest market forecasting firm with subscribers in 83 different countries provide forecasts of...

17 Sep 2016 Pechala's Reports 2 $25.00

Wright Investors Service Comprehensive Report for Orexigen Therapeutics Inc

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

27 Aug 2016 Wright Reports 65 $75.00

OREXIGEN THERAPEUTICS - IN CONTROL OF ITS OWN DESTINY

Orexigen has completed the reacquisition of the US rights to Contrave from Takeda, putting it in control of its own destiny a...

19 Aug 2016 Edison Investment Research 7 $10.00